BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
This meets the minimum requirement for their exchange offer. Now, BioNTech will provide ADSs or cash for any fractional ADSs to the shareholders who participated, and they've also opened up another offering period until December 18.
Once that period wraps up, they'll go ahead with a post-offer reorganization.
BNTX is currently trading at $97.01, up $0.90 or 0.94 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.